🇺🇸 Sofosbuvir + Daclatasvir in United States
8 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 8
Most-reported reactions
- Hepatitis B Reactivation — 3 reports (37.5%)
- Acute Kidney Injury — 1 report (12.5%)
- Crohn^S Disease — 1 report (12.5%)
- Ileal Ulcer — 1 report (12.5%)
- Salmonellosis — 1 report (12.5%)
- Spontaneous Bacterial Peritonitis — 1 report (12.5%)
Other Virology / Hepatology approved in United States
Frequently asked questions
Is Sofosbuvir + Daclatasvir approved in United States?
Sofosbuvir + Daclatasvir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Sofosbuvir + Daclatasvir in United States?
Egyptian Liver Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.